Ad
Sunday, 10 December 2017
Roche: Tecentriq cocktail slows kidney cancer progression
ZURICH (Reuters) - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment